TISIDB

Summary
Symbol	MOAP1
Name	modulator of apoptosis 1
Aliases	MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location	14q32.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF14893 PNMA
Function	Required for death receptor-dependent apoptosis. When associated with RASSF1, promotes BAX conformational change and translocation to mitochondrial membranes in response to TNF and TNFSF10 stimulation.

> Gene Ontology [ TOP ]
Biological Process	GO:0001836 release of cytochrome c from mitochondria GO:0001844 protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:0006839 mitochondrial transport GO:0007006 mitochondrial membrane organization GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008637 apoptotic mitochondrial changes GO:0010821 regulation of mitochondrion organization GO:0010822 positive regulation of mitochondrion organization GO:0035794 positive regulation of mitochondrial membrane permeability GO:0038034 signal transduction in absence of ligand GO:0046902 regulation of mitochondrial membrane permeability GO:0051204 protein insertion into mitochondrial membrane GO:0051205 protein insertion into membrane GO:0070585 protein localization to mitochondrion GO:0072655 establishment of protein localization to mitochondrion GO:0072657 protein localization to membrane GO:0090150 establishment of protein localization to membrane GO:0090199 regulation of release of cytochrome c from mitochondria GO:0090200 positive regulation of release of cytochrome c from mitochondria GO:0090559 regulation of membrane permeability GO:0097191 extrinsic apoptotic signaling pathway GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand GO:0097193 intrinsic apoptotic signaling pathway GO:0097345 mitochondrial outer membrane permeabilization GO:1902108 regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902110 positive regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902686 mitochondrial outer membrane permeabilization involved in programmed cell death GO:2001233 regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway
Molecular Function	GO:0031625 ubiquitin protein ligase binding GO:0044389 ubiquitin-like protein ligase binding
Cellular Component	GO:0005741 mitochondrial outer membrane GO:0019867 outer membrane GO:0031968 organelle outer membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	MOAP1
Name	modulator of apoptosis 1
Aliases	MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location	14q32.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MOAP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MOAP1
Name	modulator of apoptosis 1
Aliases	MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location	14q32.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MOAP1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MOAP1
Name	modulator of apoptosis 1
Aliases	MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location	14q32.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MOAP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.771	0.0108
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	1.422	0.477
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.3	0.831
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	1.17	0.00782
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	1.389	0.107
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.901	0.415
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.096	0.782
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.023	0.988
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.24	0.886
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.056	0.965
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.514	0.783
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.006	0.93

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MOAP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	2.7	4.7	0.294
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	3.4	4	0.587
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MOAP1
Name	modulator of apoptosis 1
Aliases	MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location	14q32.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MOAP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MOAP1
Name	modulator of apoptosis 1
Aliases	MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location	14q32.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MOAP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MOAP1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MOAP1
Name	modulator of apoptosis 1
Aliases	MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location	14q32.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MOAP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MOAP1
Name	modulator of apoptosis 1
Aliases	MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location	14q32.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MOAP1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MOAP1
Name	modulator of apoptosis 1
Aliases	MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location	14q32.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MOAP1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MOAP1
Name	modulator of apoptosis 1
Aliases	MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location	14q32.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MOAP1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MOAP1